

**AN IMMUNOHISTOCHEMICAL STUDY OF SURVIVIN EXPRESSION IN
NORMAL AND IN TRANSFORMED CELLS**

by

ISKANDAR ZULKARNAIN BIN ALIAS

**Thesis submitted in fulfillment of the
requirements for the degree
of Doctor of Philosophy**

**SCHOOL OF MEDICAL SCIENCES
UNIVERSITI SAINS MALAYSIA**

April 2006

ACKNOWLEDGEMENTS

I would like to express my gratitude to all those who have contributed to this work. First, I should grant my deepest appreciation and sincere thanks to my main supervisor, DR. FAWWAZ SHAKIR MAHMOUD AL-JOUDI for his extra-ordinary supervision, great help, continuous assistance, invaluable encouragement, guidance, and critical comments in the writing of this thesis, and support throughout my study.

My special thanks to my co-supervisor, Mr. Imran Abdul Khaleed from Department of Surgery, Hospital Kota Bharu (HKB) for his assistance, and providing samples and clinical data for the study. Special thanks also to Dr. Ahmad Marzuki, from Department of Surgery, and Dr. Zakaria Jusoh, Head of Pathology Department and Puan Fadzlon Abu Bakar, from Department of Pathology, Hospital Kuala Terengganu (HKT) for providing samples. I would like to thank Associate Prof. Dr. Mustafa Musa, Head of Immunology Department, Associate Prof. Dr. Hasnan Jaafar, Head of Pathology Department, Associate Prof. Dr. Hamid Mat Sain, from Department of Surgery for their assistance and providing samples and also as co-researchers in USM. I also would like to thank Dr. Kamal Yatiban, from Department of Surgery, HUSM for providing me samples for the study. I would like to thank my younger brother and sister, Dr. Mohd. Izuddin Alias and Dr. Haslizawati Alias from Hospital Kuala Terengganu (HKT) for providing clinical data and assistance over there.

My respects and thanks are due to all the staff and colleagues at the Chemical Pathology Department, School of Medical Sciences, USM especially to Associate Prof. Nor Akmal Wahab, Dr. Zulkarnain Mustafa, Encik Rafi Mustafa, and Encik Chandran Govindasami. I also would like to thank all the staff at the Animal House, USM especially to Associate Prof. Dr. Afifi Sheikh Abu Bakar, Encik Maarof Saleh, Encik

Zaini, and Encik Nor for their kindly cooperation as well as Puan Dalilati from Pharmacology Department, USM. I would like to thank Prof. Rani Samsuddin, the Dean from the School of Dental Sciences, USM who let me used the Tissue Culture Laboratory and all the staff in CranioFacial Laboratory especially Dr. Karima Akool Al-Salihi, Encik Marzuki Md. Yusof, Puan Asiah Abu Bakar and Cik Fadilah Abdullah for their kindly cooperation. My respects and thanks also due to all the staff at the Pathology Department, USM, especially to Encik Rosli Jusoh, Encik Ismail Abdul Manan, Puan Halijah Ibrahim, Puan Rushidah Yatim, and Encik Hasbullah Abdul Samad for their kindly high cooperation throughout the study.

I would like to thank all the staff at the Immunology Department, School of Medical Sciences for their assistance especially to Puan Salwa, Puan Azma, and Puan Halisa. I also would like to thank Puan Zaini, The Deputy of Director from Medical Record Unit, HUSM for allowing me in retrieving of the medical information from the patients' folders from the HUSM data base. Nevertheless, gratitude is also due to the USM for the sponsoring the two USM Shortterm Grants (304/PPSP/613218 and 304/PPSG/6131336).

I also wish to thank my father, Hj. Alias bin Ab. Ghani and family, who always give me a moral support when I need throughout the study. I also would like to thank my supportive wife, Puan Anina Sari bt. Kol.(B) Hj. Ghazali (AMN), my children, Hafizah, Abdul Aziz, Muhammad Hafizuddin, Nur Alya Marwana, and Nur Aseela Ameera, who have had to put up with me working late nights and weekends to complete my PhD study. Finally, in hoping to get blessing from Yang Maha Esa, all the "pahala" comes from this thesis, I give it to my beloved mother, Allaryarham Hajjah Habsah @ Ramlah binti Ibrahim. This thesis is a witness of my history of life, sad and happy.

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS	ii
TABLE OF CONTENTS	iv
LIST OF TABLES	xviii
LIST OF FIGURES	xxi
LIST OF PLATES	xxviii
LIST OF PHOTOS	xxxii
LIST OF ABBREVIATIONS	xxxiii
ABSTRACT	xxxv
ABSTRAK	xxxvii
CHAPTER I	INTRODUCTION
1.1	The cell cycle 1
1.1.1a	The normal cell cycle 1
1.1.1b	The cell cycle of tumour cell: tumour growth and cell proliferation 3
1.1.2	Apoptosis 4
1.1.2.1	The major elements of apoptosis 5
1.1.2.2	The extrinsic apoptosis pathway 6
1.1.2.3	The intrinsic apoptotic pathway 6
1.1.2.4	Cell morphology and physiological changes during apoptosis 8
1.1.3	Components of the apoptotic pathways 9
1.1.3.1	The caspases death proteases 9
1.1.3.2	Cytochrome c 10

1.2	Survivin	11
1.2.1	Structure and function of survivin	12
1.2.2	The mechanism of survivin inhibition of apoptosis	15
1.2.3	The role of survivin in cell division	16
1.2.4	Survivin expression in cell lines, and in embryonic, fetal and normal adult tissues	16
1.2.5	Survivin and cancer	18
1.2.6	Clinical significance of survivin	20
	1.2.6.1 Prognostic value of survivin in cancer	21
	1.2.6.2 Survivin as a therapeutic target in cancer	21
1.3	Bcl-2	22
1.3.1	Structure and biological functions of bcl-2	22
1.3.2	Bcl-2 and its role in breast cancer	24
1.3.3	The expression and clinical significance of bcl-2 in breast cancer	25
1.4	p53	27
1.4.1	Structure and biological functions of wild type p53	27
1.4.2	Mutant p53 protein and apoptosis	28
1.4.3	p53 pathways and its role in breast cancer	29
1.4.4	The expression of p53 in breast cancer	30
1.4.5	The clinical significance of p53 in breast cancer	32
1.5	Survivin, p53 and bcl-2 in breast cancer and their relationships	33

1.6	Breast cancer	33
1.6.1	Epidemiology of breast cancer	33
1.6.2	The normal anatomy and physiology of the breast	35
1.6.3	Etiology and pathogenesis	38
1.6.4	Risk factors	38
1.6.5	Pathology	39
1.6.6	Prognosis of breast cancer	40
1.6.7	Treatment of breast cancer: Chemotherapeutic drugs	41
1.6.7.1	Doxorubicin	42
1.6.7.2	Cyclophosphamide	42
1.6.7.3	5-Fluorouracil	43
1.6.7.4	Tamoxifen	43
1.6.8	Tumor markers in breast cancer	44
1.7	Technical considerations	46
1.7.1	Methods employed in detecting survivin	46
1.7.2	Technical limitations	47
1.8	Rationale of the study	47
1.9	Research methodology and factors that involved in the study design	48
1.10	Objectives	55
1.10.1	The general objective	55
1.10.2	The specific objectives	55

CHAPTER II	MATERIALS AND METHODS	56
2.1	Experimental design	56
2.2	Production of rabbit polyclonal antibody	56
2.2.1	Selection criteria of peptide immunogenic sites from survivin molecule	56
2.2.2	Structure of peptides	59
2.2.3	Conjugation of peptides to keyhole limpet hemocyanin	62
2.2.4	Choice of host, description and preparation of the animals	63
2.2.5	Preparation for immunization of animals	63
2.2.5.1	The conventional method of immunization	65
2.2.5.2	The rapid method of immunization	65
2.2.5.3	Blood withdrawal	68
2.2.6	Storage of sera	68
2.2.7	Antibody preparation	68
2.2.7.1	Preparation for the polyclonal antibody purification	68
2.2.7.2	Determination of IgG content in unpurified sera and purified sera	69
2.2.8	SDS-PAGE	71
2.2.8.1	Stock solutions	71
2.2.8.2	Preparation of slab gels	72
2.2.8.3	Preparation of samples	72
2.2.8.4	Electrophoresis of proteins	73
2.2.8.5	Staining and destaining of gels	73

	2.2.8.6	Electrophoretic transfer, immunoblotting, and preabsorption test	74
	2.2.8.6a	Western transfer	74
	2.2.8.6b	Staining of transferred proteins	77
	2.2.8.6c	Immunoblotting	77
	2.2.8.7	Preabsorption test	78
2.3		The immunohistochemistry assay	79
	2.3.1	Preparation of tissue blocks and tissue fixation	79
	2.3.1.1	Tissue processing	79
	2.3.1.2	Poly-L-lysine slides	80
	2.3.1.3	Tissue embedding, sectioning and fishing	81
	2.3.2	Haematoxylin and Eosin Staining	81
	2.3.3	Preparation of immunohistochemical staining for survivin	82
	2.3.3.1	Antigen retrieval method development and the immunoassay	82
	2.3.3.2	Chequerboard analysis	82
	2.3.3.2.1	Staining by primary and secondary antibodies	83
	2.3.3.2.1a	Selection and testing a series of primary antibody dilutions	84
	2.3.3.2.1b	Selection and testing a series of secondary antibody dilutions	84
	2.3.3.3	The scoring system for survivin expression	85

2.4	Investigations of survivin expression in breast cancer cell line, MCF-7	86
2.4.1	Cell line selection and cell cultivation	86
2.4.2	Maintenance of established cellular growth and harvesting of cells	86
2.4.3	Preparation of chemotherapeutic drugs	87
2.4.4	Cell counting and evaluation of viable cells	87
2.4.5	Tumor cell inhibition assays	88
2.4.6	The apoptosis assay	89
	2.4.6.1 Detection and quantification of apoptosis	89
	2.4.6.2 Apoptotic index	90
2.4.7	Immunocytochemistry	90
	2.4.7.1 Immunocytochemistry assay	90
	2.4.7.2 Scoring system for survivin expression	91
2.5	Investigation of survivin expression in fetuses, and normal adult animal tissues	92
2.5.1	Preparation of pregnant animals	92
2.5.2	Preparation of mouse fetuses, and adult tissues for survivin staining	93
2.5.3	Immunohistochemical staining for the detection of survivin in animal tissues	94
2.6	Survivin expression in breast cancer tissues: a clinical survey	94
2.6.1	Study design and sample size	94
	2.6.1.1 Patients selection and parameters	94
	2.6.1.2 Sample size	95
	2.6.1.3 Inclusion criteria	95

2.6.2	Clinicopathological definitions	96
2.6.3	Immunohistochemistry for survivin detection	96
2.6.4	Preparation of immunohistochemical staining for p53 and bcl-2	97
2.6.4.1	Immunostaining for p53	97
2.6.4.2	Immunostaining for bcl-2	97
2.6.5	Viewing and interpretation of survivin, p53, and bcl-2 results on slides	98
2.7	Detection of anti-survivin autoantibodies	98
2.7.1	Sera	98
2.7.2	ELISA	99
2.8	Statistical analyses	100
 CHAPTER III PRODUCTION AND STANDARDIZATION OF IMMUNOHISTOCHEMISTRY ASSAY		101
3.1	Introduction	101
3.1.1	Polyclonal antibody production	101
3.1.2	Rationale of the production of anti-survivin polyclonal rabbit antibody	103
3.2	Results	104
3.2.1	Concentration of IgG in different polyclonal anti-sera	104
3.2.2	Specificity of the antibodies	105
3.2.2.1	Western blotting	105
3.2.2.2	Preabsorption test	108
3.2.3	Standardization of the immunohistochemistry assay	109

3.2.3.1	Development of a procedure for antigen retrieval	109
3.2.3.2	Selecting the optimum polyclonal rabbit anti-survivin serum for IHC assay	116
3.2.3.3	Comparing the conventional method and the rapid method of immunization	116
3.2.3.4	Comparing sera and purified antibody products	116
3.2.3.5	Chequerboard analysis for the selected primary and secondary antibodies	117
3.2.3.5a	Determination of the optimal titers for indirect immunoperoxidase method for SUR12A- RFI	118
3.2.3.5b	Determination of the optimal titers for indirect immunoperoxidase method for SUR12A- CFI	122
3.2.3.6	Validation of immunohistochemical assay	126
3.3	Discussion	127
3.3.1	Selection of sequences and specificities	127
3.3.2	Development of an immunohistochemistry assay	129
3.3.3	Antigen retrieval method development	132
3.3.4	Validation of the assay	133
3.3.5	Technical considerations	133
3.4	Conclusions	136

CHAPTER IV	SURVIVIN EXPRESSION IN FETAL AND ADULT NORMAL TISSUES OF MOUSE AND RAT	137
4.1	Introduction	137
	4.1.1 Homologues of survivin	139
	4.1.2 Function of survivin in embryonic, fetal development and tissue differentiation	140
	4.1.3 Rationale of study	141
4.2	Results	142
	4.2.1 Overall fetal body expression and organ expression of survivin	142
	4.2.2 Expression of survivin in mouse fetus	148
	4.2.3 Expression of survivin in selected organs of adult normal tissues of rat	150
4.3	Discussion	152
	4.3.1 Expression of survivin in animal tissues	152
	4.3.2 Subcellular localization of survivin	153
	4.3.3 Structural homology of human, rat and mouse survivin	153
4.4	Conclusions	154
CHAPTER V	THE EFFECTS OF CHEMOTHERAPEUTIC DRUGS ON CELL VIABILITY, APOPTOSIS, AND SURVIVIN EXPRESSION IN MCF-7 CELLS	155
5.1	Introduction	155
	5.1.1 Morphology and characteristics of the breast cancer cell line, MCF-7	156
	5.1.2 The effect of chemotherapeutic drugs on apoptosis	156

5.1.3	Rationale of the study	158
5.2	Results	159
5.2.1	Cell viability	159
5.2.2	IC ₅₀ estimation	159
5.2.2.1	The effect of doxorubicin on cell viability of MCF-7	160
5.2.2.2	The effect of cyclophosphamide on cell viability of MCF-7	161
5.2.2.3	The effect of 5-FU on cell viability of MCF-7	162
5.2.2.4	The effect of TAM on cell viability of MCF-7	163
5.2.3	The effect of drugs inducing apoptosis	164
5.2.4	The intensity of the survivin expression in MCF-7 cell line	168
5.2.5	The subcellular localization of survivin: effects of chemotherapeutic drugs	169
5.3	Discussion	175
5.3.1	The effect of chemotherapeutic drugs on cell viability	175
5.3.2	The effect of chemotherapeutic drugs on survivin expression and its subcellular localization	176
5.3.3	The effect of chemotherapeutic drugs on apoptosis	178
5.4	Conclusions	180

CHAPTER VI	SURVIVIN EXPRESSION AND ITS SUBCELLULAR LOCALIZATION IN INFILTRATING DUCTAL CARCINOMA OF THE BREAST AND ITS RELATIONSHIP WITH CLINICOPATHOLOGICAL FACTORS, HORMONAL STATUS, P53 AND BCL-2	181
6.1	Introduction	181
6.1.1	Rationale of the study	182
6.2	Results	184
6.2.1	Patients demographics	184
6.2.1.1a	The overall distribution of cases according to age group	184
6.2.1.1b	The incidence of infiltrating ductal carcinoma of the breast in different age group according to the histopathological grade	186
6.2.1.2	The overall distribution of the cases according to the ethnic group	187
6.2.1.3	The overall distribution of cases according to the tumour size range	188
6.2.1.4	The overall distribution of cases according to the tumour side	189
6.2.1.5	The overall distribution of cases according to the lymph node status	190
6.2.1.6a	The overall distribution of cases according to the tumour histological grade	191
6.2.1.6b	The distribution of age, tumour size, ER, PR, p53,bcl-2, and survivin according to tumour histological grade	192
6.2.2	The expression of survivin and its correlation with the clinicopathological factors and hormonal status in infiltrating ductal carcinoma of the breast	194

6.2.3	The expression of p53 and its correlation with clinicopathological factors and hormonal status in infiltrating ductal carcinoma of the breast	197
6.2.4	The expression of bcl-2 and its correlation with clinicopathological factors, and hormonal status in infiltrating ductal carcinoma of the breast	201
6.2.5	The correlation between survivin, p53, and bcl-2 among the subjects	205
6.2.5.1	Correlation between survivin and p53 expression	205
6.2.5.2	Correlation between survivin and bcl-2 expression	206
6.2.5.3	Correlation between p53 and bcl-2 expression	207
6.2.6	The overall subcellular survivin expression among the survivin positive cases in infiltrating ductal carcinoma of the breast	208
6.2.6.1	The distribution and correlation of subcellular survivin expression with tumour size range	209
6.2.6.2	The distribution and correlation of subcellular survivin expression with tumour grade	210
6.2.6.3	The distribution and correlation of subcellular survivin expression with tumour side	211
6.2.6.4	The distribution and correlation of subcellular survivin expression with lymph node status	212
6.2.6.5	The distribution and correlation of subcellular survivin expression with the estrogen receptor status	213
6.2.6.6	The distribution and correlation of subcellular survivin expression with the progesterone receptor status	214

6.2.6.7	The distribution and correlation of subcellular survivin expression with p53 expression	215
6.2.6.8	The distribution and correlation of subcellular survivin expression with bcl-2 expression	216
6.2.7	The correlation between the outcome of the patients with survivin expression	217
6.2.8	Multiple regression test to see the influence of independent factors on the outcome variable (dependant factor)	219
6.2.9	Prognostic analysis in patients with IDC of the breast	221
6.3	Discussion	222
6.3.1	Patients characteristics	222
6.3.2	The expression of survivin among the infiltrating ductal carcinoma of the breast patients	225
6.3.3	The correlation between the clinicopathological factors, hormonal status and survivin, p53, and bcl-2 expression	225
6.3.4	Correlation between survivin, p53 and bcl-2 expression	226
6.3.5	Survivin expression as a diagnostic and a prognostic indicator	229
6.3.6	Subcellular localization of survivin and its prognostic factor	230
6.4	Conclusions	233

CHAPTER VII	DETECTION OF AUTOANTIBODIES TO SURVIVIN IN INFILTRATING DUCTAL CARCINOMA OF THE BREAST PATIENTS SERA	234
7.1	Introduction	234
	7.1.1 Rationale of the study	235
7.2	Results	236
	7.2.1 Detection of anti-survivin autoantibodies by indirect ELISA	236
7.3	Discussion	239
7.4	Conclusions	241
CHAPTER VIII	GENERAL DISCUSSION	242
CHAPTER IX	CONCLUSIONS and FUTURE DIRECTIONS	249
REFERENCES		251
APPENDICES		
Appendix 1	Consent Letter	299
Appendix 2	Data Collection Form	303
Appendix 3	WHO Histological Classification of Breast Tumour (1981)	309
Appendix 4	Microscopic Grading of Breast Carcinoma: Nottingham Modification of the Bloom-Richardson System	311
Appendix 5	Protocol for blood and tissue collections	312
Appendix 6	Examples of Histopathological report from HUSM, HKB, and HKT	313
Appendix 7	List of Publications	314

LIST OF TABLES

Table	Title	Page
1.1	Meta analysis of survivin expression in cancers in published reports	19
1.2	Meta analysis of bcl-2 expression in breast cancer in published reports	26
1.3	Meta analysis of p53 expression in breast cancer patients in published reports	31
1.4	Meta analysis of different technique in survivin detection in different studies using different types of specimens from previous studies	46
2.1	List of anti-survivin antibodies produced by several authors and companies and their selected survivin amino peptide sequence as a source of information for the present study	61
2.2	Recipes for SDS-PAGE preparation	72
2.3	Profile of tissues processing steps for breast cancer samples	80
2.4	Design of chequerboard analysis	85
3.1	The names of four different types of polyclonal rabbit anti-survivin sera produced by two different immunization protocols in this study	104
3.2	Estimation of concentration of total proteins (mg/ml) and IgG (mg/ml) in different polyclonal rabbit anti-survivin sera	105
3.3	The staining intensity of survivin in breast and colon cancer tissue sections according to the types and the pH of antigen retrieval buffer	111
3.4	Determination of optimal titers for indirect immunoperoxidase method for SUR12A-RFI antibody with antigen retrieval buffer Tris-EDTA, pH 9	118
3.5	Determination of optimal titers for indirect immunoperoxidase method for SUR12A-CFI antibody with antigen retrieval buffer Tris-EDTA, pH 9	122

5.1	The intensity of the survivin expression in the MCF-7 cell line after treatment with the chemotherapeutic drugs	168
6.1	The distribution of age, tumour size, survivin, p53, bcl-2, ER, PR, and lymph node metastasis according to tumour histological grade	193
6.2	The correlation between clinicopathologic factors and expression of survivin in breast cancer	196
6.3	The correlation between clinicopathologic factors and expression of p53 in breast cancer	200
6.4	The correlation between clinicopathologic factors, hormonal status, and expression of bcl-2 in breast cancer	204
6.5	The correlation between survivin and p53 in infiltrating ductal carcinoma of the breast	205
6.6	The correlation between survivin and bcl-2 in infiltrating ductal carcinoma of the breast patients	206
6.7	The correlation between p53 and bcl-2 in infiltrating ductal carcinoma of the breast patients	207
6.8	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to the tumour size range	209
6.9	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to the tumour grade	210
6.10	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to the tumour side	211
6.11	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to the lymph node status	212
6.12	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to the estrogen receptor status	213
6.13	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to the progesterone receptor status	214

6.14	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to p53 expression	215
6.15	The distribution of subcellular localization of survivin among the survivin positive infiltrating ductal carcinoma of the breast according to the bcl-2 status	216
6.16	Multiple regression “Forward Stepwise” to see the influence of other factors on the outcome alive or dead	219

LIST OF FIGURES

Figure	Title	Page
1.1	Cell cycle pathways showing its check points and regulators of a normal cell. M=Mitosis, G= Gap, S=Synthesis, R=Restriction (Andreeff <i>et al.</i> , 2000; Li <i>et al.</i> , 1998)	2
1.2	The routes of apoptosis (Reed, 2001; Borner, 2003; Bossy-Wetzel & Green, 1999; Suzuki <i>et al.</i> , 2001; Coultas & Strasser, 2003)	7
1.3	The overall architecture of human survivin. <i>a</i> , Ribbon representation of the survivin dimer. The Zn ²⁺ ion is shown as a shaded sphere. Coordination bonds are shown as dotted orange spheres. One monomer is blue; the other is rose. <i>b</i> , Orthogonal view of the ribbon representation shown in (<i>a</i>). <i>c</i> , Perspective and close up view of the Zn ²⁺ binding site on one survivin monomer. The depicted orientation corresponds to that pictured in (<i>a</i>). (Verdecia <i>et al.</i> , 2000)	14
1.4	Anatomy of normal female breast (Source : http://www.diasus.com)	37
1.5	Anatomy of normal female breast with axillary lymph nodes (Source: http://www.slp-hormones.co.uk)	37
1.9.1	Flowchart of development of immunochemical assay for detection of survivin in a variety of tissues	51
1.9.2	Flowchart of investigations of survivin expression in selected normal fetal and adult tissues in rat and mouse	52
1.9.3	Flowchart of investigation of the effect of different doses of selected chemotherapeutic drugs on the relative cell viability, apoptosis, and subcellular localization of survivin expression in the human breast cancer cell line, MCF-7	53
1.9.4	Flowchart of clinical investigation of survivin expression in human breast cancer	54
2.1	Flowchart of methodology of polyclonal antibody production	57

2.2a	Survivin molecule and the location of selected peptide in the molecule as a antigenic determinants	58
2.2b	A) Survivin-like polypeptide and its DNA (426 bp). B) Confirmation of the human survivin polypeptide sequence (GeneBank Accession No. AAC51660). The underlined sequences were the survivin amino sequences used to produce the peptides	59
2.2c	Peptide hydrophilicity analysis by using Epitope Software Analysis (Source: http://www.innovagen.se/custom-peptide-synthesis/peptide-property-calculator/peptide-property-calculator.asp)	60
2.3	Schedule of conventional immunization protocol for polyclonal rabbit antiserum antibody production in rabbits	66
2.4	Schedule of rapid immunization protocol for polyclonal rabbit antiserum antibody production in rabbits	67
2.5	Transfer sandwich and Multiphor II NovaBlot Unit for electrophoretic transfer	76
3.1a	(A) The SDS-PAGE of whole breast cancer tissue lysate in gel and (B) The completely Western blotting transfer onto PVDF membrane stained with amido black	106
3.1b	The Western blot analysis showing the specific immunoreactivity of antibodies to survivin on PVDF membrane. A) Two markers bands (arrows) stained with Amido Black B) Western blot with the preimmunized sera showed no immunoreactivity (no band) C) Western blot analysis against total protein extract from breast cancer tissue lysate showed reactivity with a single band of protein at approximately 16.5 kd, consistent with the expected molecular weight with polyclonal serum antibody, SUR12A-RFI D) Band of survivin in breast cancer tissue lysate stained with polyclonal serum antibody, SUR12A-CFI. E) Western blot with normal breast tissue lysate, no immunoreactivity	107
3.2	The plates of chequerboard titration of primary antibody SUR12A-RFI in fixed dilution of secondary antibody (1:160) colon cancer tissue sections. (Panel A) ISS +3, NSB (+3), Dilution: 1: 5 (Panel B) ISS +3, NSB (+3), Dilution: 1: 20 (Panel C) ISS +3, NSB (+2), Dilution: 1: 80 (Panel D) ISS +3, NSB (+2), Dilution: 1: 320 (Panel E) ISS +3, NSB (+2) Dilution: 1: 1280 (Panel F) ISS (0), NSB (0), Negative control : with preimmune	119

	rabbit sera (Original magnification X 400). (ISS= Intensity specific staining; NSB = nonspecific background)	
3.3a	The chequerboard titration of primary Ab SUR12A-RFI in fixed dilution of secondary Ab 1: 40	120
3.3b	The chequerboard titration of primary Ab SUR12A-RFI in fixed dilution of secondary Ab (1: 80)	120
3.3c	The chequerboard titration of primary Ab SUR12A-RFI in fixed dilution of secondary Ab 1:160	121
3.4	The plates of chequerboard titration of primary antibody SUR12A-CFI in fixed dilution of secondary antibody (1:160) colon cancer tissue sections (Panel A) ISS +3, NSB (+3) Dilution : 1: 5 (Panel B) ISS +3, NSB (+3), Dilution : 1: 20 (Panel C) ISS +3, NSS (+2), Dilution : 1: 80 (Panel D) Intensity of specific staining +3, Non-specific background (+2), Dilution : 1: 320 (Panel E) ISS +3, NSB(1+), 1: 1280 (Panel F) ISS (0), NSS (0) Negative control : with preimmune rabbit sera (Original magnification X 400).(ISS= Intensity specific staining, NSB= non-specific background	123
3.5a	The chequerboard titration of primary Ab SUR12A-CFI in fixed dilution of secondary Ab (1: 40).	124
3.5b	The chequerboard titration of primary Ab SUR12A-CFI in fixed dilution of secondary Ab (1: 80)	124
3.5c	The chequerboard titration of primary Ab SUR12A-CFI in fixed dilution of secondary Ab (1: 160).	125
4.1	Human, mouse and rat apoptosis inhibitor survivin amino sequence. The sequences used to produced SUR12A-CFI as in bold text (Ambrosini <i>et al.</i> , 1997; Uren <i>et al.</i> , 2001; Kobayashi <i>et al.</i> , 1998)	139
4.3	Plates showing the positive immunostaining of survivin in the liver during fetal development of mouse at day 18. Panel A) Original magnification x 2.5 Panel B) Arrows show the cytoplasmic staining of survivin (Original magnification x400)	149
5.1a	The effect of different concentration of doxorubicin on the relative viability of MCF-7 cell line after 72 hours. Each value represents the mean \pm s.d. of four independent triplicate experiments. Percentage values of cell viability	160

	was obtained with untreated control cells maintained under identical experimental conditions were taken as 100%.	
5.1b	The effect of different concentration of cyclophosphamide on the relative viability of MCF-7 cell line after 72 hours. Each value represents the mean \pm s.d. of four independent triplicate experiments. Percentage values of cell viability was obtained with untreated control cells maintained under identical experimental conditions were taken as 100%.	161
5.1c	The effect of different concentration of 5-fluorouracil on the relative viability of MCF-7 cell line after 72 hours. Each value represents the mean \pm s.d. of four independent triplicate experiments. Percentage values of cell viability was obtained with untreated control cells maintained under identical experimental conditions were taken as 100%	162
5.1d	The effect of different concentration of tamoxifen on the relative viability of MCF-7 cell line after 72 hours. Each value represents the mean \pm s.d. of four independent triplicate experiments. Percentage values of cell viability was obtained with untreated control cells maintained under identical experimental conditions were taken as 100%	163
5.2	Micrographs showing examples of the morphological changes and evidence of apoptosis in MCF-7 cells after 72 hours in the presence of chemotherapeutic drugs. Panel A) Showing apoptotic bodies after staining with acridine orange and propidium iodide fluorescent dyes, red colour at late apoptosis stage (white arrow) and also can be seen are a few cells in an early stage of apoptosis (blue arrow). Panel B) Showing the MCF-7 cells with no evidence of apoptosis. These microphotographs were taken using a Confocal Laser Microscope (Zeiss)	165
5.3a	Spontaneous and doxorubicin-induced apoptosis in MCF-7 cell line. The 1PPC of DOXO is 0.5 μ g/ml	166
5.3b	Spontaneous and cyclophosphamide-induced apoptosis in MCF-7 cell line. 1PPC of CYCLO is 6.0 μ g/ml	166
5.3c	Spontaneous and 5-Fluorouracil-induced apoptosis in MCF-7 cell line. 1PPC of 5-FU is 60 μ g/ml	167
5.3d	Spontaneous and tamoxifen-induced apoptosis in MCF-7	167

cell line. 1PPC of TAM is 40.0 ng/ml

- 5.4 Example of micrographs showing the expression of survivin in the human breast cancer cell line MCF-7 after incubation with chemotherapeutic drug. Plate A) Original magnification x100, intensity (+++). Plate B) Original magnification x400, intensity (+++). Most of the cells expressed predominantly cytoplasmic staining (C>N) and only a small percentage of cells showed nuclear-cytoplasmic (N/C) and exclusively cytoplasmic (C) staining of survivin. There was no predominantly nuclear (N>C) staining. The score values in the experiment was performed by the specific standard scoring system 170
- 5.5a The effect of doxorubicin on the subcellular localization of survivin. The localization of the survivin within a cell was classified as predominantly nuclear (N>C), nuclear and cytoplasmic (N/C), predominantly cytoplasmic (C>N), or exclusively cytoplasmic (C). The bars represent the mean of four independent experiments with less than 10% variation. More than 1000 cells were counted per experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The PPC of doxorubicin is 0.5 µg/ml. Most of the cells expressed cytoplasmic staining and only a small percentage expressed nuclear-cytoplasmic staining 171
- 5.5b The effect of cyclophosphamide on the subcellular localization of survivin. The localization of the survivin within a cell was classified as predominantly nuclear (N>C), nuclear and cytoplasmic (N/C), predominantly cytoplasmic (C>N), or exclusively cytoplasmic (C). The bars represent the mean of four independent experiments with less than 10% variation. More than 1000 cells were counted per experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The PPC of doxorubicin is 6 µg/ml. Most of the cells expressed cytoplasmic staining and only a small percentage expressed nuclear-cytoplasmic staining 172
- 5.5c The effect of 5-FU on the subcellular localization of survivin. The localization of the survivin within a cell was classified as predominantly nuclear (N>C), nuclear and cytoplasmic (N/C), predominantly cytoplasmic (C>N), or exclusively cytoplasmic (C). The bars represent the mean of four independent experiments with less than 10% variation. More than 1000 cells were counted per experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The PPC of doxorubicin is 60 µg/ml. Most of the cells expressed cytoplasmic staining and only a small percentage expressed nuclear-cytoplasmic staining 173

5.5d	The effect of TAM on the subcellular localization of survivin. The localization of the survivin within a cell was classified as predominantly nuclear (N>C), nuclear and cytoplasmic (N/C), predominantly cytoplasmic (C>N), or exclusively cytoplasmic (C). The bars represent the mean of four independent experiments with less than 10% variation. More than 1000 cells were counted per experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The PPC of doxorubicin is 40.0 ng/ml. Most of the cells expressed cytoplasmic staining and only a small percentage expressed nuclear-cytoplasmic staining	174
6.1a	The incidence of infiltrating ductal carcinoma of the breast according to the age group in the states of Kelantan and Terengganu	185
6.1b	The incidence of infiltrating ductal carcinoma of the breast in different age group according to the histological grade in the states of Kelantan and Terengganu	186
6.2	Distribution of infiltrating ductal carcinoma of the breast cases according to ethnicity	187
6.3	Tumour size distribution according to the range of tumour size (cm)	188
6.4	The distribution of tumour side among the infiltrating ductal carcinoma of the breast patients	189
6.5	The distribution of lymph node involvement cases among the infiltrating ductal carcinoma of the breast	190
6.6	The distribution of histological grades of the tumour in infiltrating ductal carcinoma of the breast	191
6.7	Overall subcellular localization of survivin in survivin positive tissues among the infiltrating ductal carcinoma of the breast patients (n=260/382)	208
6.8	The survivin status among the dead and alive patients from 1992 to 2000 until December 2004 (Pearson Chi-square= 43.509, p< 0.001)	217
6.9a	The survivin score according to the outcome of the infiltrating ductal carcinoma of the breast patients with positive of survivin staining	218

6.9b	Kaplan-Meier curves for overall 5-year survival rates of infiltrating ductal carcinoma of the breast patients categorized according to survivin expression. No significant difference was found between the groups (p=0.4; log-rank test)	221
7.1	The cutoff point of positivity for autoantibodies to survivin at 0.059 and the optical density distribution among the subject according to the groups and internal negative control	237
7.2	The mean, standard deviation and standard error of the each group in the study	238

LIST OF PLATES

Plate	Title	Page
3.1a	A micrograph showing the immunostaining of survivin (arrows) scoring ++(++), and in category 3 of positivity in breast cancer tissue section with antigen retrieval buffer, citrate buffer, pH 6 with dilution of primary SUR12A-CFI antibody 1: 1280 and secondary antibody dilution 1: 160 (Original magnification x 400).	112
3.1b	A micrograph showing the immunostaining of survivin (arrows) scoring +++ (+), and in category 4 of positivity in breast cancer tissue section with antigen retrieval buffer Tris-EDTA pH 9, with dilution of primary SUR12A-CFI antibody 1: 1280 and secondary dilution antibody 1: 160 (Original magnification X 400)	112
	Note: +++ (+) = intensity of specific staining (intensity of background staining). A mean percentage of positive tumor cells was determined in at least five areas at X 400 magnification and assigned to one of the five following categories: (a) 0, < 5%; (b)1, 5-25%; (c)2, 26-50%, (d) 3, 51-75%; and (e) 4, > 75%. The intensity of survivin immunostaining was scored as follows: (a) weak, +; (b) moderate, ++; (c) intense, +++	
3.1c	A micrograph showing the internal negative control of breast cancer tissues section scoring 0 (0) with citrate buffer, pH 6 (A) and 0 (0), Tris-EDTA buffer, pH 9 (B), with preimmune rabbit sera (Original magnification x 400)	113
3.2a	A micrograph showing the immunostaining of survivin (arrows) with scoring +++ (+), and in category 3 of positivity in colon cancer tissue section with antigen retrieval buffer, citrate buffer, pH 6 with dilution of primary SUR12A-CFI antibody 1: 1280 and secondary antibody dilution 1: 160 (Original magnification X 400)	114

- 3.2b A micrograph showing the immunostaining of survivin (arrows) with scoring +++ (\pm), and in category 4 of positivity in colon cancer tissue section with antigen retrieval buffer Tris-EDTA pH 9, with dilution of primary SUR12A-CFI antibody 1: 1280 and secondary dilution antibody 1: 160 (Original magnification X 400). 114
- Note: +++ (+) = intensity of specific staining (intensity of background staining). A mean percentage of positive tumor cells was determined in at least five areas at X 400 magnification and assigned to one of the five following categories: (a) 0, < 5%; (b)1, 5-25%; (c)2, 26-50%, (d) 3, 51-75%; and (e) 4, > 75%. The intensity of survivin immunostaining was scored as follows: (a) weak, +; (b) moderate, ++; (c) intense, +++.
- 3.2c A micrograph showing the negative control of colon cancer tissue sections scoring 0 (+) with citrate buffer, pH 6 (left) and 0 (0) with Tris-EDTA buffer, pH 9 (right), with preimmune rabbit sera (Original magnification x 400) 115
- 3.3 A micrograph showing the immunostaining of survivin (arrows) with +++ (+), and in category 4 of positivity in colon cancer tissue section with antigen retrieval buffer Tris-EDTA pH 9, with dilution of primary polyclonal antibody FL-142 Santa Cruz 1: 200 and secondary dilution antibody 1: 160 (Original magnification x400). 115
- Note: +++ (+) = intensity of specific staining (intensity of background staining). A mean percentage of positive tumor cells was determined in at least five areas at X 400 magnification and assigned to one of the five following categories: (a) 0, < 5%; (b)1, 5-25%; (c)2, 26-50%, (d) 3, 51-75%; and (e) 4, > 75%. The intensity of survivin immunostaining was scored as follows: (a) weak, +; (b) moderate, ++; (c) intense, +++
- 3.4a Survivin staining in formalin-fixed paraffin-embedded breast cancer tissue sections showing strong score but no staining in the adjacent breast normal tissue (Original magnification x400) 126
- 3.4b A micrograph showing the cytoplasmic (red arrow) and nuclear (yellow arrows) staining of survivin in paraffin-embedded breast cancer tissue sections (Original magnification x400) 126

4.1a	A micrograph showing overall positive immunostaining of survivin (red arrows: intense and blue arrows; weak staining) during development of rat fetal taking using digital camera Fuji Model FinePicA310 with close up mode. This section showed parts of the organs in fetus	142
4.1b	A micrograph showing overall positive immunostaining of survivin (red arrows: intense and blue arrows; weak staining) during development of mouse fetal taking using digital camera Fuji Model FinePicA310 with close up mode. This section shows parts of the organs in fetus	143
4.2a	A micrograph showing the positive immunostaining of survivin (black arrow) in formalin-fixed paraffin embedded section of the skin during the fetal rat development at day 18. Red arrow is showing the germinal layer of the epidermis. Original magnification x100	144
4.2b	An example of micrograph showing an abundance of positive immunostaining of survivin in formalin-fixed paraffin embedded section of adrenal tissue during fetal rat development (arrows) at day 18. A) Original magnification x100 B) Original magnification x400	145
4.2c	Micrograph showing positive immunostaining of survivin in a formalin-fixed paraffin embedded section of liver tissue during fetal development of rat at day 18 (brown color). A) Original magnification x100 B) Original magnification x400	145
4.2d	A micrograph showing positive immunostaining of survivin in a formalin-fixed paraffin embedded section of stomach tissue during fetal development of rat at day 18 A) Original magnification x100 B) Original magnification x400	146
4.2e	A micrograph showing positive immunostaining of survivin in a formalin-fixed paraffin embedded section of intestine during fetal development of rat at day 18 A) Original magnification x100 B) Original magnification x400	146
4.2f	A micrograph showing positive immunostaining of survivin in a formalin-fixed paraffin embedded section of colon during fetal development of rat at day 18. Original magnification x100	147

4.2g	A micrograph showing positive immunostaining of survivin in formalin-fixed paraffin-embedded tissue section of kidney during fetal development of rat at day 18. The staining is predominantly at the cytoplasm of the proximal tubules cells A) Original magnification x 2.5 B) Original magnification x 400	147
4.4a	A micrograph showing positive staining of survivin in formalin-fixed paraffin embedded section of the kidney in adult normal rat. The staining is predominantly at the cytoplasm (arrow) of the proximal tubules cells A) Original magnification x100 B) Original magnification x400	151
4.4b	A micrograph showing positive immunostaining of survivin in a formalin-fixed paraffin embedded section of the ovary of normal adult rat. Original magnification x2.5	151
6.1a	A micrograph showing the positive immunostaining of survivin in breast cancers (Original magnification x400)	195
6.2a	A micrograph showing the positive immunostaining of p53 in breast cancer (Original magnification x100)	199
6.2b	A micrograph showing the nuclear positive immunostaining of p53 (arrow) in breast cancer (Original magnification x400)	199
6.3a	A micrograph showing the cytoplasmic positive immunostaining of bcl-2 in breast cancer tissue section (Original magnification x100)	202
6.3b	A micrograph showing the cytoplasmic positive immunostaining of bcl-2 in breast cancer tissue section (Original magnification x400)	202
6.3c	A micrograph showing the negative control of bcl-2 in an inflamed tonsillar tissue section (Original magnification x400)	203
6.3d	A micrograph showing the positive control of bcl-2 in an inflamed tonsillar tissue section (Original magnification x400)	203

LIST OF PHOTOS

Photo	Title	Page
2.1	The New Zealand White rabbit used for polyclonal rabbit antiserum antibody	64
2.2	The processing before blood withdrawal in a rabbit	64

LIST OF ABBREVIATIONS

PCD	Programmed cell death
TNF	Tumor necrosis factor
IAPs	Inhibitor of apoptosis protein
FADD	Fas-associated death domain
DNA	Deoxyribonucleic acid
Apaf-1	Apoptotic protease activating factor-1
ATP	Adenosine triphosphate
T _c	The rate of cell division
M	Mitosis
G ₁	Growth phase
S	Synthesis phase
G ₂	Growth 2 phase
G ₀	Quiescent phase
UV	Ultra violet
R	Restriction point
kDa	kilo Dalton
AP14	Apoptosis inhibitor 4
cDNA	Complementary DNA
EPR-1	Effector cell protease receptor 1
BIR	Baculovirus inhibitor
INCEP	Inner centromere proteins
AI	Apoptotic index
CYCLO	Cyclophosphamide
5-FU	5-Fluorouracil
TAM	Tamoxifen
DOXO	Doxorubicin
IL3	Interleukin
PR	Progesterone receptor
3+	+++
2+	++
1+	+
ISS	Intensity specific staining
NSB	Non-specific background staining
ER	Estrogen receptor
N>C	Predominantly nuclear
N/C	Nuclear and cytoplasmic
C>N	Predominantly cytoplasmic
C	Exclusively cytoplasmic
IHC	Immunohistochemistry staining
h	Hour
PBS	Phosphate-buffered saline
OD	Optical density
Mol/L	Molar/ Liter
SDS-PAGE	Sodium dodecyl sulphate-polyacrylamide gel electrophoresis

PVDF	Polyvinylidene fluoride
BSA	Bovine serum albumin
IgG	Immunoglobulin G
DAB	3,3'-diaminobenzidine tetrahydrochloride
M	Molar
TBS	Tris-buffered saline
RT	Room temperature
HRP	Horseradish peroxidase
pAb	Polyclonal antibody
mAb	Monoclonal antibody
SUR	Survivin
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
V	Voltage
min	Minute
AR	Antigen retrieval
DMSO	Dimethyl sulphoxide
H ₂ O ₂	Hydrogen peroxide
mRNA	Messenger RNA
MW	Molecular weight
RNA	Ribonucleic acid
RT-PCR	Reverse transcription-polymerase chain reaction
ABC	Avidin-biotin-complex
df	Degree of freedom
H&E	Heamatoxylin & eaosin staining
kbp	Kilobase pair
MDM-2	Murine double minute
PPC	Peak plasma concentration

**AN IMMUNOHISTOCHEMICAL STUDY OF
SURVIVIN EXPRESSION IN NORMAL AND IN TRANSFORMED CELLS**

ABSTRACT

Survivin is a new member of the inhibitors of apoptosis protein (IAP) family, selectively over-expressed in common human cancers but not in normal adult tissues. It is also expressed in cancer cell lines. The study was performed generally to investigate the basic and clinical roles of survivin in normal and transformed cells. Rabbits were immunized with two synthetic oligopeptides, MGAPTLPPAWQP and KEFEETAKKVRRAIEQLAAMD amino acids sequences of the survivin molecule. Serum antibodies were purified by ammonium sulphate and caprylic acid and their specificities were confirmed by immunoblotting and pre-absorption tests against survivin positive tissues or synthetic survivin oligopeptides. These antibodies were used to detect survivin in normal and transformed cells by immunohistochemistry in formalin-fixed paraffin embedded tissue sections, evaluated by a standard scoring system and checkerboard analysis. Normal cells were obtained from fetal and adult tissues of mouse and rat whilst the transformed cells were obtained from the human breast cancer cell line MCF-7 and the infiltrating ductal carcinoma (IDC) of the breast patients. In the MCF-7 cell line experiment, the effects of chemotherapeutic drugs namely doxorubicin, 5-fluorouracil, cyclophosphamide, and tamoxifen on the apoptosis index measured by propidium iodide and acridine orange dyes. The relative cell viability was measured by an MTT assay and survivin expression was measured by immunocytochemistry. In IDC patients (n=382), survivin expression in tissues was analyzed for its correlation with clinical pathological factors, hormonal status, p53, bcl-2 and the survival rate. Patients and their tissue blocks were obtained from three general hospitals in The East Coast of Malaysia. Autoantibodies to survivin were also investigated in the sera of the same IDC patients population (n=57) and were compared

to the control population (n=44). For the immunohistochemistry assay, four rabbit antiserum were produced and tested against survivin. The results of this study indicated that the antigen retrieval buffer, pH 9 was superior than pH 6 and optimization immunohistochemistry was obtained by checkerboard analysis. Furthermore, it was found that survivin is expressed abundantly in normal growing fetal cells but not in normal differentiated adult tissues of mouse and rat. In the MCF-7 cell line, the cell viability was reduced in a dose-dependent pattern when incubated with the drugs. The IC₅₀ estimation in MCF-7 cell line for doxorubicin was 6.0 µg/ml, cyclophosphamide 171.1 µg/ml, 5-fluorouracil 0.61µg/ml, and tamoxifen 0.7µg/ml, respectively. It was found that most of the MCF-7 cells expressed survivin, predominantly in the cytoplasm. The percentages of apoptotic cells were increased with the increased concentrations of the drugs. Among the IDC patients, the expression of survivin was 68.1%, p53 29.6%, and bcl-2 43.7%, respectively. There was a significant correlation (p<0.05) between survivin expression and lymph node involvement, tumour sizes, p53, bcl-2 expression, and survival rate among the IDC patients. Anti-survivin autoantibodies reactivities were detected in 7% of the sera of IDC patients but not in normal sera. These autoantibodies correlated with the positivity of survivin expression, and with advanced breast cancer. It was concluded that survivin was abundantly and prominently expressed during fetal development of rat and mouse. The polyclonal antibody SUR12A-CFI recognized rat and mouse survivin. It was also concluded that survivin is frequently over-expressed in IDC patients, and in most MCF-7 cells. Survivin expression has a predictive value in predicting the aggressiveness of the tumour cells suggesting that survivin may be a useful tool in assessing a prognosis.

**KAJIAN IMUNOHISTOKIMIA
TERHADAP EKSPRESI SURVIVIN DI
DALAM SEL NORMAL DAN SEL TERTRANSFORMASI**

ABSTRAK

Survivin merupakan ahli baru dalam keluarga protin perencat apoptosis, secara terpilih diekspres secara berlebihan dalam kebanyakan kanser tetapi tidak di dalam tisu dewasa normal. Ia juga diekspres di dalam rangkaian sel-sel kanser. Kajian ini dilakukan bagi mengkaji secara asas dan klinikal tentang survivin di dalam sel normal dan sel tertransformasi. Arnab telah diimunkan dengan sintetik oligopeptida, jujukan asid amino, MGAPTLPPAWQP dan KEFEETAKKVRRAIEQLAAMD daripada molekul survivin. Antibodi serum ditulenkan dengan ammonium sulfat dan asid caprilik dan speksifikasinya telah disahkan dengan teknik immunoblot dan ujian penyerapan awal terhadap tisu positif survivin dan sintetik oligopeptida survivin. Antibodi ini telah digunakan untuk mengesan survivin di dalam sel normal dan sel tertransformasi menggunakan kaedah imunohistokimia pada hirisan tisu formalin-paraffin dan diukur menggunakan kaedah sistem penskoran piawai dan analisis optimasi. Sel normal diperolehi daripada tisu fetus dan tisu dewasa tikus dan mencit manakala sel tertransformasi diperolehi daripada rangkaian sel kanser payu dara MCF-7 dan pesakit karsinoma infiltrasi kelenjar payu dara. Di dalam kajian rangkaian sel MCF-7, kesan dadah kemoterapi iaitu Doxorubicin, 5-Fluorourasil, Cyclophosphamide dan Tamoxifen ke atas indek apoptosis yang diukur dengan kaedah propidium iodida dan akridin oren. Relatif sel viabiliti diukur dengan ujian MTT dan ekspresi survivin diukur dengan kaedah immunositokimia. Korelasi antara faktor klinikopatologi, status hormon, p53, bcl-2 dan kadar hidup di kalangan pesakit kanser payu dara (n=382) telah dianalisa. Blok-blok tisu daripada pesakit telah diperolehi daripada tiga hospital utama di Pantai

Timur. Autoantibodi terhadap survivin juga telah dikaji di dalam serum pesakit kanser payu dara (n=57) dan dibandingkan dengan kumpulan kawalan (n=44). Keputusan kajian mendapati, empat antiserum telah berjaya dihasilkan dan diuji terhadap survivin secara immunohistokimia. Larutan penampan pemulihan antigen pH 9 adalah lebih baik berbanding dengan pH 6 dan optimasi telah diperolehi dengan kaedah analisis optimasi. Survivin didapati diekspres di dalam sel normal fetus mencit dan tikus yang aktif tetapi tidak pada sel normal yang telah membeza. Nilai IC₅₀ bagi rangkaian sel MCF-7 untuk Doxorubixin ialah 6.0 µg/ml, Cyclophosphamide 171.1 µg/ml, 5-Fluorourasil 0.61 µg/ml dan Tamoxifen 0.7 µg/ml. Didapati survivin diekspres kebanyakannya di sitoplasma. Peratus sel apoptotik meningkat dengan peningkatan dos dadah. Di kalangan pesakit kanser payu dara, survivin diekspres sebanyak 68.1%, p53 29.6% dan bcl-2 43.7%. Terdapat korelasi yang bererti (p<0.05) di antara ekspresi survivin dengan metastasis nodus limfa, saiz tumor, p53, bcl-2 dan kadar hidup di kalangan pesakit yang dikaji. Sebanyak 7% autoantibodi terhadap survivin dikesan di kalangan pesakit tetapi tidak pada kumpulan kawalan. Autoantibodi didapati berkorelasi dengan ekspresi survivin dan tahap akhir kanser. Kesimpulan kajian ialah survivin banyak diekspres pada sel normal yang aktif membahagi dan sel tertransformasi. Antibodi SUR-12A-CFI dapat mengesan survivin pada tikus dan mencit. Survivin juga secara berlebihan diekspres di kalangan pesakit kanser payu dara dan rangkaian sel MCF-7. Survivin juga mungkin boleh digunakan untuk meramal keagresifan sel tumor dan dicadangkan survivin boleh menjadi alat untuk membuat penilaian prognosis.

CHAPTER I

INTRODUCTION

1.1 The cell cycle

1.1.1a The normal cell cycle

Normal cells of multi-cellular organisms can divide as often as once or twice a day *in vivo*. The rate of cell proliferation within any population of cells depends on three parameters: a) the rate of cell division (T_c), (b) the fraction of cells within the population undergoing cell division (growth fraction), and (c) the rate of cessation of cell division due to terminal differentiation or cell death (Andreeff *et al.*, 2000).

Cellular reproduction is a cyclic process in which daughter cells are produced through nuclear division (mitosis) and cellular division (cytokinesis). Mitosis (M) and cytokinesis are part of the growth-division cycle called the cell cycle (Fig.1.1). Mitosis lasts for about 1 hour, and takes a relatively small part of the total cell cycle. Interphase is the mitosis preparatory stage which is divided into 3 phases, G_1 , S, and G_2 (Fig 1.1). The first gap phase, G_1 which lasts for about 6 hours to several days or longer, is a period of growth and metabolic activity following a previous mitosis (Fig. 1.1). The synthesis phase (S phase) follows G_1 and is a period of DNA synthesis, in which the DNA is replicated. Another gap phase, G_2 which lasts about 2 hours, follows DNA synthesis and precedes the next mitotic division. Certain mature cell types do not continue to divide but remain in interphase (in G_0). Cells that are permanently in the G_0




Figure 1.1: Cell cycle pathways showing its check points and regulators of a normal cell. M=Mitosis, G= Gap, S=Synthesis, R=Restriction (Andreief *et al.*, 2000; Li *et al.*, 1998).

phase are in a quiescent state and are called post-mitotic (Andreeff *et al.*, 2000; Levine 1997; Adam *et al.*, 2001; Banks *et al.*, 2000; Bartek & Lukas, 2001; Bursch *et al.*, 2000).

The timing and ordering of cell cycle transitions are dependent on separate positive and negative regulatory circuits. The regulatory circuits enforce a series of checkpoints, allowing passage only after completion of critical cell cycle events. Two classes of regulatory pathways exist, intrinsic and extrinsic. Intrinsic regulatory pathways are responsible for the precise ordering of the cell cycle events. Since the lengths of S, G₂, and M phases in mammalian cells are relatively invariant, the transitions between these phases are controlled predominantly by intrinsic regulatory pathways. Extrinsic regulatory pathways function in response to environmental conditions or in response to detected cell cycle defects. Both types of regulatory pathways can use the same checkpoints (Andreeff *et al.*, 2000; Evans & Vousden, 2001).

When DNA is damaged by alkylating agents or by UV radiation, cells initiate a response that includes cell cycle arrest, apoptotic cell death, and transcriptional induction of genes involved in DNA repair. Normal cells in G₁ phase prior to the restriction point (R) will arrest in G₁ phase upon sensing DNA damage (Fig. 1.1) (Andreeff *et al.*, 2000; Budiharjo *et al.*, 1999; Fernandez *et al.*, 1998; Fu *et al.*, 2004).

1.1.1b The cell cycle of tumour cell: tumour growth and cell proliferation

Cancer is a disease of accumulation of clonally expanded cells. Tumour cell numbers increase, and the tumour burden accounts for the adverse effects on the host (Andreeff *et al.*, 2000). Thus, cancer is a disease of uncontrolled proliferation. The

mechanisms that underly tumour and normal cell proliferation are very similar (Andreeff *et al.*, 2000). Both bcl-2 and p53 play a role in determining tumour growth by their effects on apoptosis and cell proliferation (Linjawi *et al.*, 2004). Hence, tumour growth is the net result of cell proliferation and cell death (Siziopikou & Schnitt, 2000).

P53 is the guardian or the master brake in the cell cycle. When some cellular mechanism goes wrong, the wild p53 will stop the cell from dividing, but if the wild p53 is altered to a mutant p53, it can no longer stop the cell from dividing. As the situation is not an abnormal control of the cell control but the cell cycle can no longer be controlled if there are genetically altered cells (Levine, 1997; Park *et al.*, 1997; Moreno *et al.*, 2001; Nakahara *et al.*, 1998; Shiratsuchi *et al.*, 2002).

1.1.2 Apoptosis

Apoptosis or programmed cell death (PCD) is a universal and physiological process responsible for removing unwanted, old, damaged, and misplaced cells during embryonic development and tissue homeostasis (Sreedhar & Csermely, 2004; Borner, 2003; Andreeff *et al.*, 2000; Eissa *et al.*, 1999; Strasser *et al.*, 1997). The study of apoptosis has emerged from relative obscurity to become a major focus of research interest in many areas of medicine in the last decade (Rudin *et al.*, 1997).

Apoptosis is derived from Greek and refers to the dropping or falling of leaves from a tree (Sreedhar & Csermely, 2004). The term was introduced by Kerr *et al.*, (1972) to define the morphologic features of the apoptotic process. Some promoter and suppressor genes control this process (Sirvent *et al.*, 2004; Roninson *et al.*, 2001).

1.1.2.1 The major elements of apoptosis

Apoptosis is well characterized by distinct morphological and physiological changes (Sirvent *et al.*, 2004). The p53 protein is also involved in both the extrinsic and the intrinsic pathways of apoptosis by initiating apoptosis through mitochondrial depolarization and sensitizing cells to inducers of apoptosis (Hofseth *et al.*, 2004). Apoptosis is induced by an array of internal and external stimuli or signals and its mechanism has several common elements regardless of the ultimate biochemical pathways utilized (Kiechle & Zhang, 2002). Apoptosis can be divided into three phases. The first phase is the initiation phase (or signalling phase), which involves the activation of surface death receptors (extrinsic pathways), mainly the tumour necrosis factor (TNF) family members, the mitochondrial pathway (intrinsic pathway) or the initiation of apoptosis by other stimuli (e.g., those affecting the endoplasmic reticulum (ER)). The second is the signal transduction phase (or preparation phase), where activation of initiator caspases (caspase-8, caspase-9, caspase-10, and caspase-12) and certain kinases/phosphatases takes place. This is followed by the execution phase (or death phase), which involves the activation of effector caspases (caspase-3, caspase-6, and caspase-7) (Fig. 1.2) (Bronchud *et al.*, 2000; Thornberry & Lazebnik, 1998).

Mammals have two distinct apoptosis signalling pathways, extrinsic and intrinsic (Coultas & Strasser, 2003). Signalling through both the extrinsic and intrinsic pathways can be modulated by IAPs (inhibitor of apoptosis proteins) such as bcl-2 and survivin, which are highly conserved polypeptides that selectively inhibit the activation and functional activity of various caspases (Kaufmann & Earnshaw, 2000; Reed, 1999; Sanna *et al.*, 2002; Deveraux & Reed, 1999; Campora *et al.*, 2000; Parton *et al.*, 2001).

1.1.2.2 The extrinsic apoptotic pathway

This is a receptor-linked pathway that requires the binding of a ligand to a death receptor on the cell surface. For example, the cytokine, tumour necrosis factor (TNF), binds to the death receptor, TNF receptor type 1 (TNFR1), which recruits two signal transducing molecules; TNFR 1-associated protein with a death domain, and a Fas-associated polypeptide containing a death domain (FADD). This complex then binds to procaspase 8 to activate caspase 8, which, in turn initiates the protease cascade leading to apoptosis (Fig. 1.2) (Bronchud *et al.*, 2000; Lockshin *et al.*, 2000; Uno *et al.*, 2002).

1.1.2.3 The intrinsic apoptotic pathway

This pathway is mediated by the mitochondrial release of cytochrome c (Kiechle & Zhang, 2002; Pruschy *et al.*, 2001). It is mainly activated when damaged DNA is not sensed and repaired by checkpoint genes. Initiation of apoptosis may occur immediately or it may be delayed following the DNA damage. The response may or may not be dependent on the presence of the nuclear transcription factor, p53. When p53 is upregulated, it is activated by the phosphorylation of serine 46 by the homeodomain-interacting protein kinase-2, and the two proteins cooperate in the activation of the p53-dependent transcription. (Bronchud *et al.*, 2000; Levine 1997). Proteins induced by p53 include Bax, a bcl-2 homologous protein, which oligomerizes and forms pores in the outer mitochondrial membrane, resulting in either a decrease in the inner mitochondrial transmembrane potential or opening of the voltage-dependant anion channel, releasing cytochrome c from the space between the inner and outer mitochondrial membranes (Heiser *et al.*, 2004). Cytosolic cytochrome c induces the




Figure 1.2 : The routes of apoptosis (Reed, 2001; Borner, 2003; Bossy-Wetzel & Green, 1999; Suzuki *et al.*, 2001; Coultas & Strasser, 2003)

formation of the multisubunit apoptosome composed of apoptotic protease activating factor-1 (Apaf-1), procaspase 9 and either ATP or dATP. Caspase 3 then mediates the apoptotic cascade (Heiser *et al.*, 2004; Bronchud *et al.*, 2000). IAPs of both cellular and viral origin have been identified to be intrinsic cellular suppressors of apoptosis that block the apoptotic program in response to viral infection or other forms of stresses such as survivin (Pruschy *et al.*, 2001; Li & Li, 2000; Thomas, 2000; Shu *et al.*, 1997).

1.1.2.4 Cell morphology and physiological changes during apoptosis

The process of apoptosis involves a cell dying in the midst of surviving cells, in contrast to necrosis, which involves clusters of dying cells in an area associated with an inflammatory infiltrate. Apoptosis occurs as a single cell death surrounded by healthy cells. The morphological changes in apoptosis can be seen by light microscopy, and have been characterized further by electron microscopy (Archer *et al.*, 2000). These include nuclear (chromatin) condensation with the chromatin forming clumps that gather adjacent to the nuclear membrane (nuclear periphery). Furthermore, the cytoplasm condenses leading to cell shrinkage due to contraction of the cell and loss of volume, and to cell rounding due to loss of adhesion to surrounding cells and membrane blebbing. These bodies with condensed nuclear chromatin and, once released into the extra-cellular space, are rapidly ingested by phagocytic cells (Coultas & Strasser, 2003; Robertson *et al.*, 2000; Wylie & Currie, 1980; Gonzalez-Campora *et al.*, 2000).

The major physiological changes comprise fragmentation of nuclear DNA due to activation of specific endonucleases cleaving nuclear DNA into 80-200 oligonucleosomal fragments, and the activation of caspases, resulting in partially

digested proteolytic protein products (Sreedhar & Csermely, 2004; Bronchud *et al.*, 2000). This process produces cell breaking into several fragments of nuclei and cytoplasm or both nuclei and cytoplasm, known as apoptotic bodies (Sirvent *et al.*, 2004). Thus, DNA fragmentation is a characteristic biochemical marker of apoptosis.

1.1.3 Components of the apoptotic pathways

The key elements which execute the apoptotic process have been studied (Borner, 2003). Over the years, many components of the apoptotic pathways have been characterized, revealing apoptosis to be a highly complex process. However, a pattern is emerging with a series of early events that depend on the initial stimulus, followed by a common pathway involving a series of cysteine proteases, the caspases. This common pathway ultimately results in DNA fragmentation and morphological changes associated with apoptosis. Mitochondria have emerged as having a central role in the process and its regulation, with the bcl-2 family of proteins playing a particularly important part (Strasser *et al.*, 1997; Kaufman & Gores, 2000; King & Cidlowski, 1995).

1.1.3.1 The caspase death proteases

Caspase is a nomenclature referring to ICE/CED-3 cysteine proteinase family having a central role during cell death (Suzuki *et al.*, 2001) and in executing the process of apoptosis (Fig. 1.2) (Borner, 2003). In mammals, 14 members of the caspase family have been identified which cleave their substrates after aspartic acid (Asp). Activation of pro-caspases requires two caspases cleaved at the aspartic acid (Asp) residues (Strasser *et al.*, 1997). These cleavages remove the amino-terminal pro-domain and

separate the large and small catalytic subunits. Once activated, caspases can process and activate their own subunits and other pro-caspases (Bossy-Wetzel & Green, 1999). Caspase activation is not reversible and leads to cell apoptosis (Gompel *et al.*, 2004).

These enzymes are minimally active in healthy cells and require further activation in response to apoptotic stimuli such as ionizing radiation, chemotherapeutic drugs, and death receptor ligands (Shi, 2002; Alarcon & Ronai *et al.*, 2002; Pruschy *et al.*, 2001). They are divided into two categories; initiator caspases and effector caspases. The former includes caspase-2, caspases 8- to 10, and caspase-12, which are activated in response to a cell death signal, and the latter includes caspase-3, caspase-6 and caspase-7 which transmit the signal activating the cascade that results in DNA fragmentation and cell death (Subsection 1.1.2.4) (Kawamura *et al.*, 2003; Earnshaw *et al.*, 1999).

1.1.3.2 Cytochrome c

Cytochrome c is a protein that is normally stored in the intermembrane space of mitochondria (Scorrano *et al.*, 2003). When the cell receives an apoptotic signal, cytochrome c crosses the outer mitochondrial membrane and accumulates in the cytosol where it functions as a cofactor in the activation of caspases (Fig. 1.2) (Bossy-Wetzel & Green, 1999). Cytochrome c triggers a post-mitochondrial pathway forming an oligomeric complex of cytochrome c/ apoptotic protease activating factor-1 (Apaf-1)/caspase-9, the “apoptosome”, which activates the initiator caspase-9 to subsequently cleave the effector caspase-3 and caspase-7 to cause nuclear fragmentation (Scorrano *et al.*, 2003; Kaufmann & Earnshaw, 2000). The treatment of HeLa cells with

staurosporine, a potent pro-apoptotic agent, causes the release of cytochrome c from the mitochondria into the cytosol (Kaufmann & Earnshaw, 2000; Michalides, 1999).

1.2 Survivin

Survivin is a 16.5-kDa protein also known as AP14 or BIRC5. It is an intracellular protein that inhibits apoptosis and regulates cell division and belongs to the inhibitors of apoptosis (IAP) gene family (Verdacia *et al.*, 2000; Altieri, 2001). Members of the IAP family prevent cells from apoptosis, by inhibiting caspases (Fig. 1.2) (Wojcik *et al.*, 2002; Yamamoto & Tanigawa, 2001). Survivin was discovered in 1997 by hybridization screening of a human genomic library with the cDNA of the effector cell protease receptor-1 (EPR-1) (Ambrosini *et al.*, 1997). The survivin gene spans 15 kb, and is located on chromosome 17 t band q25. Survivin has an unusual relationship to EPR-1 in that its sequence is complementary to and in the reverse orientation of EPR-1. The coding strand of survivin contains an open reading frame of 426 nucleotides, and encodes a protein of 142 amino acids (Chiou *et al.*, 2003).

Survivin over-expression *in vivo* increases cell resistance to apoptosis (Chiou *et al.*, 2003). This conclusion has been proven by the study of Grossman *et al.*, (2001a) when transgenic expression of survivin in epidermal keratinocytes significantly reduced the number of apoptotic cells in the epidermis following exposure to ultraviolet (UV) irradiation. Conversely, inhibition of survivin expression *in vitro*, by treatment with antisense survivin oligonucleotide, increased the susceptibility of HeLa cells to receptor-mediated apoptosis, and the human neural tumour cell lines to induced apoptosis, MSN and TC620 (Shankar *et al.*, 2001).

Survivin appears to have an important role in regulating apoptosis at the cell cycle checkpoint(s). Its expression is highly cell cycle-regulated, and is detectable in the nucleus selectively at the G2/M phase (Li *et al.*, 1998). Transcription of survivin has been shown to be directly repressed by wild-type p53, another cell cycle checkpoint-regulating protein that induces apoptosis (Mirza *et al.*, 2002). When acute lymphoblastic leukemia cells are treated with doxorubicin, which causes accumulation of wild type p53, the result is a dramatic down-regulation of survivin, depletion of cells in the G2/M phase of the cell cycle, and increased apoptosis (Zhou *et al.*, 2002).

In addition, survivin appears to be important for cell cycle progression. Disruption of survivin by antisense targeting HeLa cells results in spontaneous apoptosis and aberrant mitosis, as well as an increase in caspase-3 activity at mitosis. Disruption of survivin in cell lines by both antisense targeting and survivin antibodies also induces polyploidy and aneuploidy as a result of cytokinesis failure and the premature onset of anaphase. *In vivo*, survivin is also required for cell division. Homozygous knockout of the survivin gene in mouse embryonic stem cells resulted in disrupted microtubule formation and polyploidy during development, which culminated in early embryonic lethality (Uren *et al.*, 2000).

1.2.1 Structure and function of survivin

The structure of human survivin, as determined by X-ray crystallography, reveals the presence of an amino-terminal globular zinc finger domain, which includes the BIR motif, and a long carboxy-terminal helix separated by a short linker segment, important for dimerization (Rodriguez *et al.*, 2002). The structure of survivin is

intimately linked with its function as an inhibitor of apoptosis. The amino terminal portion of survivin consists of three alpha helices (residues 14-21, 31-41, 68-80) and 3 beta-sheets (residues 43-45, 55-58, 61-64), which closely resemble the BIR domain that is conserved in the IAP family (Fig 1.3). The BIR domains of IAP family members are involved in the function of these proteins as inhibitors of apoptosis (Verdecia *et al.*, 2000). A mutation in the BIR domain, T34A, which inhibits phosphorylation of survivin by p34-cyclin B1, abrogates the ability of survivin to inhibit apoptosis (Chiou *et al.*, 2003).

Three different isoforms of this protein have been identified: survivin (142 aa), survivin-2B (165 aa) and survivin- Δ Ex3 (137 aa) (Mahotka *et al.*, 1999). Survivin and survivin-2B are located in the cytoplasm whereas survivin- Δ Ex3 is located in the nucleus. Another isoform was reported in 2004 by Badran *et al.* 2004 designated as survivin 3B (120 aa) in human adenocarcinoma cell lines. It is likely that survivin-3B possesses anti-apoptotic activity. Survivin- Δ Ex3 has anti-apoptotic properties whilst survivin-2B with markedly reduced anti-apoptotic properties (Badran *et al.*, 2004). It was reported that the localization in distinct cellular compartments of different nuclear-cytoplasmic variants might constitute a regulatory mechanism for the activity of different splice variants of survivin. The different isoforms of survivin is believed to play a distinct role in cancer and therefore that such a role may be partially determined by their differential nuclear-cytoplasmic transport and localization (Rodriguez *et al.*, 2002).




Figure 1.3: The overall architecture of human survivin. *a*, Ribbon representation of the survivin dimer. The Zn^{2+} ion is shown as a shaded sphere. Coordination bonds are shown as dotted orange spheres. One monomer is blue; the other is rose. *b*, Orthogonal view of the ribbon representation shown in (*a*). *c*, Perspective and close up view of the Zn^{2+} binding site on one survivin monomer. The depicted orientation corresponds to that pictured in (*a*). (Verdecia *et al.*, 2000)

1.2.2 The mechanism of survivin inhibition of apoptosis

Survivin is identified as an intrinsic cellular regulator that plays an important role in the suppression of apoptosis by either directly or indirectly inhibiting the activity of caspases (Hikita *et al.*, 2002; Badran *et al.*, 2003; Badran *et al.*, 2004; Bao *et al.*, 2002; Honda *et al.*, 2003; Kuttler *et al.*, 2002; Li *et al.*, 1998; Song *et al.*, 2004; Song *et al.*, 2003). Several IAP family members have been shown to suppress apoptosis by direct inhibition of caspases via the BIR domains. The structure of survivin has been compared to another IAP family member, XIAP, which contains three BIR domains (Tran *et al.*, 1999; Otaki *et al.*, 2000; Shinozawa *et al.*, 2000; Sohn *et al.*, 2003). XIAP inhibits caspase-3 and caspase-7 via a linker region between the first two domains, and also binds to and inhibits caspase-9 through its third BIR domain (BIR3). The BIR domain of survivin appears to be closely related in its three dimensional structure to the BIR3 domain of XIAP, suggesting the possibility that survivin binds caspase-9. Survivin has a capability to bind to caspases and modulate their functions (Kawamura *et al.*, 2003; Sandler *et al.*, 2002; Sarela *et al.*, 2001; Wheatley *et al.*, 2001; Mahotka *et al.*, 2002; Kornacker *et al.*, 2001; Krieg *et al.*, 2002). The interaction between survivin and caspase-9, and the functional implication of this interaction have been studied through mutagenesis. Loss of phosphorylation at threonine 34 on the T34A mutant of survivin results in the dissociation of an immunoprecipitable survivin-caspase-9 complex on the mitotic apparatus, allowing caspase-9 dependent apoptosis to occur (Chiou *et al.*, 2003; Wall *et al.*, 2003; Li *et al.*, 1999; Lu *et al.*, 2004; Fortugno *et al.*, 2003).

1.2.3 The role of survivin in cell division

Recent reports demonstrated how survivin may act in regulating cell division. During the cell cycle, survivin is first detected on the centromere at prophase/metaphase. It is also present in the spindle midzone during anaphase/telophase, but is no longer detected by the end of telophase (Li *et al.*, 1998; Uren *et al.*, 2000). Furthermore, it was indicated that survivin remains localized in kinetochores until metaphase, then in the spindle midzone during anaphase, and in the cleavage plane during telophase. The kinetochore is a DNA-protein complex that assembles on the centromere and its required for attachment of the microtubules during mitosis (Uren *et al.*, 2000). These localization patterns resemble those of the inner centromere proteins (INCENP), TD-60, and Aurora B, which are known as chromosomal passenger proteins. Thus, based on its localization during the cell cycle, it has been postulated that survivin may be an additional chromosomal passenger protein. These four proteins are the only mammalian passenger proteins known to date, which are carried on the chromosomes to the center of the cell at metaphase, in the plane of the future cleavage furrow, and are important for cytokinesis and chromosomal movements during cell division (Chiou *et al.*, 2003). It was concluded that the primary role of survivin is to regulate chromosome segregation and cytokinesis (Uren *et al.*, 2001)

1.2.4 Survivin expression in cell lines, and in embryonic, fetal, and normal adult tissues

The regulation of apoptosis is critical for normal embryonic development and for homeostasis in adult tissues (Grossman *et al.*, 2001b). In animals, survivin is strongly expressed in embryonic and fetal organs, but is undetectable in most terminally

differentiated normal tissues (Mori *et al.*, 2002). Uren *et al.*, (2001) found that survivin is expressed in mouse embryos. In the mouse model, survivin was found to be elevated at the G₂/M phase of the cell cycle during liver regeneration (Deguchi *et al.*, 2002). Kim *et al.*, (2003) reported that survivin is strongly expressed at the bottom of mouse embryonic intestinal crypts. At the protein level, survivin was also detected during all stages of early embryos of mice (Kawamura *et al.*, 2003; Jaskoll *et al.*, 2001).

The expression of survivin in normal human adult tissues, appeared only in a few published reports, contrary to numerous reports examining the role of survivin in cancer (Chiou *et al.*, 2003). However, its expression has been reported in a few normal growing adult human tissues, including thymus (Kobayashi *et al.*, 2002), colonic mucosa (Gianani *et al.*, 2001), placenta (Shiozaki *et al.*, 2003; Lehner *et al.*, 2001), bone marrow (Altieri & Marchisio, 1999), and keratinocytes of the basal layer of the skin (Grossman *et al.*, 2001a; O'Driscoll *et al.*, 2003; Chiodino *et al.*, 1999).

During human development, survivin is expressed in the fetal lung, heart, liver, kidney, and gastrointestinal tract, and in fetal tissues where apoptosis occurs, such as the stem cell layers of stratified epithelia, endocrine glands, pancreas and thymic medulla. In all of these studies, survivin was not found in normal adult tissues. These findings suggest that the regulation of cell division and the anti-apoptosis functions of survivin are important not only during early development, but also during cancer progression (Chiou *et al.*, 2003).

In cell lines, it was reported that survivin was expressed in HeLa cells (Uren *et al.*, 2001), human breast cancer cell line, MCF-7 (Tanaka *et al.*, 2004), melanoma cell

lines (Ambrosini *et al.*, 1998; Grossman *et al.*, 1999), a lung adenocarcinoma cell line (Olie *et al.*, 2000), neuroblastoma and oligodendroglioma cell lines (Shankar *et al.*, 2001), a murine thymic lymphoma cell line (Kanwar *et al.*, 2001) and a colorectal cancer cell line (Mesri *et al.*, 2001), human colon adenocarcinoma cells, HT29 (Yamamoto *et al.*, 2002).

1.2.5 Survivin and cancer

One of the most significant features of survivin is its differential distribution in cancer compared to normal tissue. Over-expression of survivin has been demonstrated in tumours of the lung, breast (Zhang *et al.*, 2004), esophagus, pancreas, bladder, uterus, cervix, ovary (Mei *et al.*, 2001; Tarkowski *et al.*, 2001; Tao *et al.*, 2004), large-cell non-Hodgkin's lymphoma, leukemias (Schlette *et al.*, 2002; Mori *et al.*, 2002; Carter *et al.*, 2001; Carter *et al.*, 2003), neuroblastomas, melanomas, gastric (Li *et al.*, 2004; Lu *et al.*, 1998; Yu *et al.*, 2002), colon (Sarela, *et al.*, 2000; Sarela *et al.*, 2001; Yang *et al.*, 2004), stomach, liver (Chiou *et al.*, 2003), oral (Muzio *et al.*, 2004; Muzio *et al.*, 2003; Muzio *et al.*, 2001), thyroid (Sugawara *et al.*, 2002), and in laryngeal squamous cell (Dong *et al.*, 2002).

Despite its role in mitosis, it is clear that the over-expression of survivin in cancer does not simply reflect the presence of a higher number of proliferating cells. In melanoma, survivin expression was indistinguishable in cases with low or high mitotic index. In addition, the fact that survivin is typically observed in nearly all tumour cells, and not just in the mitotic fraction, suggests that expression of the survivin gene is

Table 1.1 : Meta analysis of survivin expression in cancers in published reports

Authors	Method of detections	Subjects/locations	Findings/conclusions
Li <i>et al.</i> , (2004)	Immunohistochemistry (IHC)	Gastric carcinoma (n=80), China	Survivin (SUR) expression was 76%, no expression in adjacent normal tissues, +ve expression of SUR correlated with worse histological grades and pathological grades, poor prognosis. SUR inhibit apoptosis of tumor cells.
Fields <i>et al.</i> , (2004)	IHC	Hepatocellular carcinoma (n=72)	SUR expression was 43%, SUR correlated with histological grade & stage , nuclear expression correlated with poor prognosis.
Zhang <i>et al.</i> , (2004)	IHC	Breast carcinoma (n=119), China	SUR expression was 72.3%, correlated with poor prognosis.
Kayaselcuk <i>et al.</i> , (2004)	IHC	Breast carcinoma (n=43), Turkey	SUR +ve correlated with Bcl-2 but was not correlated with p53, bax, cerbB-2, estrogen & progesteron, clinicopathological factors (grade, stage and mitotic index).
Yao <i>et al.</i> , (2004)	IHC	Gastric adenocarcinoma (n=120), China	SUR expression was 49.17% in cytoplasm of carcinoma cells.
Kennedy <i>et al.</i> , (2003)	IHC	Primary breast carcinoma (n=293), Dublin, Ireland	SUR expression was 60%, 31% nuclear staining, 13% cytoplasmic, 16% both nuclear & cytoplasmic staining. Nuclear expression is most common and is an independent prognostic indicator of good prognosis.
Kawamura <i>et al.</i> , (2003)	RT-PCR & IHC	9 weeks mouse embryos	SUR protects embryo from apoptosis by inhibiting apoptotic pathway involving caspases.
Kobayashi <i>et al.</i> , (2002)	IHC, RT-PCR, flow cytometry	Human tymocytes, Japan.	SUR play an important role in the T-cell development in the human thymus. SUR has a positive correlation with Bcl-2 and CD69.
Ikehara <i>et al.</i> , (2002)	IHC	Small adenocarcinoma of lung (n=79), Japan	SUR expression was 57%, correlated with venous invasion, worse overall survival, poor prognosis.
Mori <i>et al.</i> , (2002)	Reverse PCR	Leukemia (n=31), Japan	SUR expression was 54% in acute myelocytic leukemia, 69% in acute lymphocytic leukemia, no expression in normal bone marrow, provide prognostic information.
Dong <i>et al.</i> , (2002)	IHC	Laryngeal squamous cell carcinoma(LSCC), (n=102), Japan	SUR expression was 65.7%, associated with tumor site, poor differentiation, tumor size, lymph node metastasis & advanced stage, unfavorable clinicopathological factors.
Hattori <i>et al.</i> , (2001)	RT-PCR	Epithelial ovarian cancer (n=43), Japan	SUR expression was 86%,
Mei <i>et al.</i> , (2001)	IHC	Cervical carcinoma (n=59), China	SUR expression was 69.5%, strongly associated with Bcl-2.
Lehner <i>et al.</i> , (2001)	IHC	Archival formalin-fixed human placenta tissues (n=25)	SUR expression was 68%
Tanaka <i>et al.</i> , (2000)	IHC	Breast carcinoma (n=167)	SUR expression was 70.7%
Lu <i>et al.</i> , (1998)	IHC	Gastric carcinoma (n=174), Japan	SUR expression was 34.5%, coexpression with Bcl-2 and segregated with p53 positive.

deregulated in cancer, albeit still retaining cell-cycle periodicity in mitosis (Chiou *et al.*, 2003; Daidone *et al.*, 2001; Endoh *et al.*, 2001; Frost *et al.*, 2002; Gu & Lin, 2004).

In certain cancers, two types of molecular abnormalities have been reported that might contribute to aberrant survivin expression. Gain of chromosome 17q is the most common genetic abnormality in neuroblastoma, where amplification of the survivin locus on 17q25 has been detected by fluorescence *in situ* hybridization (Chiou *et al.*, 2003; Takai *et al.*, 2002). In addition, survivin exon1 sequences are largely silenced by methylation in normal ovaries, but become de-methylated, and thus transcriptionally active, in most ovarian cancers, leading to the over-expression of survivin (Hattori *et al.*, 2001). However, given the widespread survivin over-expression in many types of cancer, it is plausible that multiple oncogenic signalling pathways might converge on the reactivation of the survivin gene in neoplasia (Chiou *et al.*, 2003).

The role of survivin in many cancers has been reported in numerous publications, but little has been published about the role of survivin in breast cancer. A few reports have shown the expression of survivin in breast cancer ranging from 60% to 72.% (Zhang *et al.*, 2004; Kennedy *et al.*, 2003; Tanaka *et al.*, 2000).

1.2.6 Clinical significance of survivin

Recently, survivin has emerged as a diagnostic and prognostic marker and a potential drug target because it is predominantly overexpressed in most cancer types. The role of survivin in the inhibition of apoptosis in breast cancer has not been clearly established. Furthermore, only a few reports have highlighted the clinical significance of

survivin. Further investigations of survivin during tumour growth and progression may yield important insights into its functional role(s) in carcinogenesis and allow the development of important therapeutic strategies for combating cancer.

1.2.6.1 Prognostic value of survivin in cancer

Assessment of prognosis is important in patients with malignancies because its results serve to separate a large heterogeneous population into smaller populations with more concisely predictable outcome (Hayes, 2000). In the majority of neoplasms investigated for survivin expression including breast, lung, colorectal, gastric, liver, bladder and kidney cancers, neuroblastoma, gliomas, soft tissue sarcomas and hematological malignancies, high levels of the IAP proteins were predictive of tumour progression, either in terms of disease-free survival or overall survival, thus providing prognostically relevant information (Zaffaroni & Daidone 2002; Altieri 2001; Altieri & Marchisio 1999).

1.2.6.2 Survivin as a therapeutic target in cancer

Two general considerations make survivin an attractive therapeutic target in cancer: it is selectively expressed in tumour cells and it is required for their viability (Chiou *et al.*, 2003; Altieri, 2003b; Ueda *et al.*, 2002; Sasaki *et al.*, 2002; Poetker, 2002; Pizem *et al.*, 2004; Iurlaro *et al.*, 2004; Guan *et al.*, 2004). Results obtained by different studies aimed at targeting survivin by means of different approaches demonstrated that inhibition of this cell survival factor promotes some favourable biological effects (Zaffaroni & Daidone 2002; Altieri, 2003a; Altieri 2004; Tsurama *et al.*, 2004).

There are several therapeutic strategies targeted to survivin including the use of antisense oligonucleotides; natural antisense (EPR-1 cDNA), oligonucleotide 4003, and oligonucleotides 903 and 904 (Ambrosini *et al.*, 1998; Grossman *et al.*, 1999; Olie *et al.*, 2000; Shankar *et al.*, 2001), dominant negative mutants: Cys 84 → Ala, Thr 34 → Ala, and Cys 84 → Ala (Grosman *et al.*, 1999; Grossman *et al.*, 2001a; Mesri *et al.*, 2001b; Kanwar *et al.*, 2001), and ribozymes (hammerhead ribozymes) (Pennati *et al.*, 2002). The biological effects *in vitro* and *in vivo* using these therapeutic strategies demonstrated as decrease in cell proliferation, an increased spontaneous apoptosis and an enhanced efficacy of several types of conventional treatments including chemotherapy, radiotherapy and immunotherapy (Zaffaroni & Daidone 2002).

1.3 Bcl-2

1.3.1 Structure and biological functions of bcl-2

B-cell lymphoma-2 protein (Bcl-2) is the first known regulator of cell death (Heiser *et al.*, 2004). The bcl-2 family proteins are important regulators of apoptosis in mammalian cells (Schinzel *et al.*, 2004). Bcl-2 is an anti-apoptotic protein (Townsend *et al.*, 2002; Giatromanolaki *et al.*, 2001) and is a proto-oncogene (Formby *et al.*, 1999; Strasser *et al.*, 1997) that resides on the cytoplasmic face of the mitochondrial outer membrane, in the endoplasmic reticulum and in the nuclear envelope (Mullauer *et al.*, 2001; Robertson *et al.*, 2000; Schinzel *et al.*, 2004). Bcl-2 is an acronym for the B-cell lymphoma/leukemia-2 gene which was identified at the site of the t(14;18) chromosomal translocation, occurring in 85% of diffused B-cell lymphomas (Joosens *et al.*, 1998; Strasser *et al.*, 1997).

The bcl-2 inhibits apoptosis (Eissa *et al.*, 1999) by blocking the release of cytochrome c from mitochondria, thereby preventing Apaf-1 (apoptotic protease-activating factor-1) and consecutive caspase activation (Fig. 1.2). The bcl-2 may also inhibit apoptosis by binding to the pro-apoptotic molecules Bax and bcl-x_s (Mullauer *et al.*, 2001).

A number of proteins that are structurally related to bcl-2 (Bcl-2 protein family) have been discovered in mammals, birds, frogs, nematodes and viruses and can be subdivided into two groups. The first group includes those that inhibit apoptosis (mammalian Bcl_L, Bcl-w, A1, Mcl-1, nematode Ced-9, adenovirus E1B19kD, Epstein Barr Virus (EBV) BHRF1, African Swine Fever Virus LMW5-HL, Human Herpes Virus 8 KSBcl-2 and Herpes Virus Saimiri ORF16). The second group includes those that enhance apoptosis (Bax, Bcl-x_s the product of alternative splice variant of the bcl-x gene, Bad, Bak, Bik/Nbk, Bid and Harakiri (Strasser *et al.*, 1997). The bcl-2 family of proteins appears to be involved in either enhancing or opposing the apoptotic process.

In most situations, the mitochondria act as focal points in the apoptotic pathway and provide convenient positions for regulatory molecules to intervene. In cell free systems, nuclear condensation and DNA fragmentation were found to be dependent on the presence of mitochondria and inhibited by bcl-2 (Heiser *et al.*, 2004).

Bcl-2 plays a crucial role in maintaining the viability of cells that are meant to be long-lived such as peripheral lymphocytes (Strasser *et al.*, 1997). The involvement of bcl-2 in apoptosis was first seen indirectly when it was noted to prolong cell survival. Immature pre-B cells dependent on IL-3 for survival in culture were noted to persist

despite IL-3 withdrawal when the cells were transfected with bcl-2, an effect that seemed to occur without cell proliferation. This persistence was later shown to be due to the ability of bcl-2 to block apoptosis (Bossy-Wetzel & Green, 1999).

The bcl-2 family of proteins is also involved in embryogenesis where it controls developmentally programmed cell death during tissue differentiation. After birth, bcl-2 and its relatives play critical roles in regulating programmed cell death in the haematopoietic system, tissue homeostasis and mammary gland involution (Coultas & Strasser, 2003).

1.3.2 Bcl-2 and its role in breast cancer

In normal breast, bcl-2 is expressed in the non-pregnant and non-involuting mammary epithelium. Bcl-2 expression has previously been reported in normal breast ductal cells where it is supposed to be involved in the hormonal regulation of hyperplasia and involution (Vetrani *et al.*, 1995). Bcl-2 is thought to be expressed through hormone-dependent pathways (Ioachim *et al.*, 2000; Vetrani *et al.*, 1995) such as estrogen and progesterone (Park *et al.*, 2002).

The exact mechanism and the effect of the down regulation of bcl-2 expression on breast cancer cells are not clearly defined (Park *et al.*, 2002). In breast cancer, bcl-2 expression appears to be inversely correlated with the presence of p53 mutations in its pathways (Joosens *et al.*, 1998; El-Ahmady *et al.*, 2002; Takei *et al.*, 1999; Van-Slooten *et al.*, 1998).